BridgeMD
New treatment option for Sickle Cell Disease
Official title Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
ClinicalTrials.gov ID: NCT07246265
What this study is testing
What is Injection of iohexol for glomerular filtration rate (GFR) measurement?
Injection of iohexol for glomerular filtration rate (GFR) measurement is an investigational medicine, given as an once-daily injectable medicine, being studied as a potential treatment for sickle cell disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Background: Sickle cell disease is a genetic disorder of haemoglobin (which carries oxygen in red blood cells). The shape of sickle cell-patients' red blood cells is abnormal.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient ≥ 18 years old
- Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0
- Admitted in an intensive care unit
- Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome
- Receiving PCA treatment with morphine
You likely can't join if
- Patient previously included in the study during a previous stay
- Injection of iodinated contrast medium outside the scope of the study within 24 hours prior to inclusion, or scheduled within 9 hours following the...
- Contraindication to iohexol: known or suspected immediate or delayed hypersensitivity, thyrotoxicosis.
- Patient undergoing morphine treatment or substitution treatment such as methadone or buprenorphine prior to hospitalization (having received morphine...
- Chronic liver disease likely to interfere with morphine metabolism (cirrhosis )
- Any condition that contraindicates the use of morphine according to the summary of product characteristics
See the full eligibility criteria
- Patient ≥ 18 years old
- Known homozygous sickle cell disease SS, SC, S-beta+, or S-beta0
- Admitted in an intensive care unit
- Clinical diagnosis of vaso-occlusive crisis and/or acute chest syndrome
- Receiving PCA treatment with morphine
- Patient's consent for study participation and/or from a relative if case of patient's incapacity
- Affiliation to social protection
- Patient previously included in the study during a previous stay
- Injection of iodinated contrast medium outside the scope of the study within 24 hours prior to inclusion, or scheduled within 9 hours following the scheduled time of iohexol injection
- Contraindication to iohexol: known or suspected immediate or delayed hypersensitivity, thyrotoxicosis.
- Patient undergoing morphine treatment or substitution treatment such as methadone or buprenorphine prior to hospitalization (having received morphine or a derivative regardless of the route of administration in the week...
- Chronic liver disease likely to interfere with morphine metabolism (cirrhosis )
- Any condition that contraindicates the use of morphine according to the summary of product characteristics
- Patients under legal protection
- Pregnant or breastfeeding women Exclusion criteria :
- Need for extrarenal epuration within 24 hours of inclusion
The study team makes the final eligibility decision.
Where it's taking place
- Tours, France, France
- Créteil, France
- Le Mans, France
- Nantes, France
- Orléans, France
- Rennes, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tours, France, France; Créteil, France; Le Mans, France; Nantes, France; Orléans, France; Rennes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.